ABSCIENCES (EPA:AB) AB SCIENCE - EXERCISE OF THE OVER-ALLOTMENT OPTION

Transparency directive : regulatory news

04/05/2010 18:00

Not for distribution directly or indirectly in the United States, Canada,
                           Australia or Japan

                                                  Paris, May 04, 2010- 6:00 pm

Total initial public offering size increased to EUR31.6 million post exercise
                    in full of the over-allotment option

AB Science announced today in relation to its initial public offering
that the Lead manager and Bookrunner, Société Générale Investment Banking,
on behalf of the Underwriters, has exercised in full the overallotment option,
resulting in the purchase of 325,515 additional existing shares at the offering
price of EUR12.65 per share.

As a result, the total number of AB Science shares offered to the market in
connection with its IPO amounts to 2,495,609 shares, or approximately 8.22% of
AB Science group's share capital and voting rights (i.e. a free float of 9.0%
post conversion of the convertible bonds into 237.154 ordinary shares).

  The total size of the IPO, Public Offering & Global Placement, increased to
                                 EUR31.6 million.

In addition, Société Générale, in its capacity as stabilising agent, has
informed AB Science that no stabilisation was carried out during the
stabilisation period, which started on April 23th, 2010 (after the issue of AB
Science 's press release announcing the results of the offering) and ended
today.

Public information

Copies of the Prospectus are available free of charge from the Company and
from the Lead Manager and Bookrunner and the Joint-Lead Manager. The Prospectus
may be viewed on the websites of the Company (www.ab-science.com) and the AMF
(www.amf-france.org). The legal and financial documents required to be made
available to shareholders may be consulted at the registered office of the
Company, 3 avenue George V, 75008 Paris. The attention of investors is drawn to
Section 4, "Risk Factors", contained in the Document de base registered with
the AMF, the update of such Document de base filed with the AMF and to Section
2 "Risk Factors" contained in the Note d'opération.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase inhibitors (PKIs),
a new class of targeted molecules whose action is to modify signalling pathways
within cells. Through these PKIs, the Company targets diseases with high unmet
medical needs (cancer, inflammatory diseases and central nervous system
diseases), in both human and veterinary medicines. Thanks to its extensive
research and development capabilities, AB Science has its own portfolio of
molecules. Masitinib, a lead compound, has already been registered in veterinary
medicine in Europe and is pursuing three on-going phases 3 in human medicine in
pancreatic cancer, GISTand mastocytosis.
AB Science is listed on NYSE Euronext Paris (Compartment B) -
ISIN: FR0010557264 - Ticker: AB

Further information is available on AB Science's website: www.ab-science.com

Financial Communication & Press Relations

Contacts Citigate Dewe Rogerson:
Agnès Villeret - Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr
Matthieu Pirouelle - Tel : +33 1 53 32 84 77 - matthieu.pirouelle@citigate.fr

Disclaimer

This press release, together with the material set forth herein, does not
constitute an offer of securities for sale nor the solicitation of an offer to
purchase securities in any jurisdiction. Distribution of such press release in
certain jurisdiction may constitute a breach of applicable laws and regulation.

In particular:

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any financial instruments in the United States. Securities
mentioned in this document have not been and will not be registered under the
Securities Act of 1933, as amended (the "Securities Act") and may not be offered
or sold in the United States absent registration or an exemption from the
registration requirements of the Securities Act. Any public offer of securities
in the United States shall be made by means of a prospectus that may be obtained
from the issuer containing detailed information regarding the Company, its
management andfinancial statements. The Company does not intend to register this
offering in all or in part or to make a public offer of securities in the United
States.

This press release is not an invitation nor is it intended to be an inducement
to engage in investment activity for the purpose of section 21 of the Financial
Services and Markets Act 2000, as amended ("FSMA"). This document is directed
only at (i) persons outside the United Kingdom; or (ii) persons in the United
Kingdom that are "qualified investors" within the meaning of Article 2(1)(e) of
Directive 2003/71/EC including any relevant implementing measure in each member
state, that are also (a) persons authorised under FSMA or otherwise having
professional experience in matters relating to investments and qualifying as
investment professionals under article 19 of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion
Order"); or (b) institutions or corporations qualifying as high net worth
persons under Article 49(2)(a) to (d) of the Financial Promotion Order; or (c)
any other persons to whom this document for the purposes of Section 21 of FSMA
can otherwise lawfully be made (all such persons together being referred to as
"Relevant Persons"). Any person in the United Kingdom that is not a Relevant
Person should not act or rely on this document.

This document contains forward-looking statements. No guarantee can be given as
to any of the events anticipated by the forward-looking statements, which are
subject to inherent risks, including those described in the Prospectus, changes
in economic conditions, the financial markets or the markets in which AB
Science operates.

ABSCIENCES's latest news

15/05/2024 20:16

ABSCIENCES (EPA:AB) AB SCIENCE - EXERCISE OF THE OVER-ALLOTMENT OPTION

Transparency directive : regulatory news

ABSCIENCES's latest news

Other stories